(NASDAQ: GALT) Galectin Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Galectin Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast GALT's revenue for 2025 to be $2,246,343,222, with the lowest GALT revenue forecast at $2,246,343,222, and the highest GALT revenue forecast at $2,246,343,222. On average, 1 Wall Street analysts forecast GALT's revenue for 2026 to be $11,113,585,176, with the lowest GALT revenue forecast at $11,113,585,176, and the highest GALT revenue forecast at $11,113,585,176.
In 2027, GALT is forecast to generate $23,826,576,623 in revenue, with the lowest revenue forecast at $23,826,576,623 and the highest revenue forecast at $23,826,576,623.